[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA41349A - Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn - Google Patents

Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn

Info

Publication number
MA41349A
MA41349A MA041349A MA41349A MA41349A MA 41349 A MA41349 A MA 41349A MA 041349 A MA041349 A MA 041349A MA 41349 A MA41349 A MA 41349A MA 41349 A MA41349 A MA 41349A
Authority
MA
Morocco
Prior art keywords
eradication
rna
guided
herpes
simplex type
Prior art date
Application number
MA041349A
Other languages
English (en)
Inventor
Kamel Khalili
Pamela C Roehm
Sayed Masoud Shekarabi
Hassen Wollebo
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of MA41349A publication Critical patent/MA41349A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA041349A 2015-01-14 2016-01-13 Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn MA41349A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562103354P 2015-01-14 2015-01-14
US201562238288P 2015-10-07 2015-10-07

Publications (1)

Publication Number Publication Date
MA41349A true MA41349A (fr) 2017-11-21

Family

ID=56406388

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041349A MA41349A (fr) 2015-01-14 2016-01-13 Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn

Country Status (12)

Country Link
US (1) US20180000970A1 (fr)
EP (1) EP3244932A4 (fr)
JP (2) JP7305301B2 (fr)
CN (1) CN107580504A (fr)
AU (1) AU2016206692B2 (fr)
BR (1) BR112017014986A2 (fr)
CA (1) CA2973722A1 (fr)
HK (1) HK1249056A1 (fr)
MA (1) MA41349A (fr)
MX (1) MX2017009324A (fr)
WO (1) WO2016115355A1 (fr)
ZA (1) ZA201704840B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6261500B2 (ja) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ ヌクレアーゼ切断特異性の評価および改善
WO2014144761A2 (fr) 2013-03-15 2014-09-18 The General Hospital Corporation Augmentation de la spécificité pour la modification du génome à guidage arn
WO2014204578A1 (fr) 2013-06-21 2014-12-24 The General Hospital Corporation Utilisation de nucléases foki à guidage arn (rfn) afin d'augmenter la spécificité pour l'édition de génome par guidage arn
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
EP4036236A1 (fr) * 2015-08-28 2022-08-03 The General Hospital Corporation Nucléases crispr-cas9 modifiées
IL310721A (en) 2015-10-23 2024-04-01 Harvard College Nucleobase editors and their uses
AU2016343991B2 (en) 2015-10-30 2022-12-01 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating herpes simplex virus
CA3032699A1 (fr) 2016-08-03 2018-02-08 President And Fellows Of Harvard College Editeurs de nucleobases d'adenosine et utilisations associees
EP3497214B1 (fr) 2016-08-09 2023-06-28 President and Fellows of Harvard College Protéines de fusion cas9-recombinase programmables et utilisations associées
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3525832A4 (fr) * 2016-10-14 2020-04-29 The General Hospital Corp. Nucléases spécifiques de site à régulation épigénétique
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
WO2018118586A1 (fr) * 2016-12-22 2018-06-28 Agenovir Corporation Polythérapie antivirale/endogène
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
WO2018165504A1 (fr) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression de la douleur par édition de gène
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
EP3601568A1 (fr) * 2017-03-31 2020-02-05 Agenovir Corporation Thérapeutique antivirale
AU2018254616B2 (en) 2017-04-21 2022-07-28 The General Hospital Corporation Inducible, tunable, and multiplex human gene regulation using crispr-Cpf1
AU2018254619B2 (en) 2017-04-21 2022-07-21 The General Hospital Corporation Variants of Cpf1 (CAS12a) with altered PAM specificity
WO2018209320A1 (fr) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
US11441135B2 (en) * 2017-07-07 2022-09-13 Toolgen Incorporated Target-specific CRISPR mutant
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3668980A1 (fr) * 2017-08-15 2020-06-24 Intellia Therapeutics, Inc. Acides nucléiques stabilisés codant pour de l'acide ribonucléique messager (arnm)
BR112020003596A2 (pt) 2017-08-23 2020-09-01 The General Hospital Corporation nucleases de crispr-cas9 engenheiradas com especificidade de pam alterada
EP3676376A2 (fr) 2017-08-30 2020-07-08 President and Fellows of Harvard College Éditeurs de bases à haut rendement comprenant une gam
US11713452B2 (en) * 2017-09-08 2023-08-01 University Of North Texas Health Science Center Engineered CAS9 variants
CN107630018B (zh) * 2017-09-30 2018-10-12 深圳三智医学科技有限公司 一种用于编辑或修复hbb基因的试剂盒
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
WO2019152868A1 (fr) * 2018-02-01 2019-08-08 Editas Medicine, Inc. Méthodes et compositions associées à crispr/cas pour le traitement de la kératite liée au virus de l'herpès simplex
WO2019224748A1 (fr) * 2018-05-22 2019-11-28 Anthrocryptex Inc. Systèmes et procédés de modulation de la pigmentation de la peau
JP7531914B2 (ja) * 2018-09-19 2024-08-13 ザ・ユニバーシティ・オブ・ホンコン 改良されたハイスループットコンビナトリアル遺伝子改変システムおよび最適化されたＣａｓ９酵素変異体
EP3918071A1 (fr) * 2019-02-01 2021-12-08 Editas Medicine, Inc. Procédés liés à crispr/cas et compositions ciblant les génomes viraux
WO2020191245A1 (fr) 2019-03-19 2020-09-24 The Broad Institute, Inc. Procédés et compositions pour l'édition de séquences nucléotidiques
KR20230019843A (ko) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
US20240271128A1 (en) * 2020-10-02 2024-08-15 Temple University - Of The Commonwealth System Of Higher Education Rna guided eradication of herpes simplex type i and other related human herpesviruses
WO2023086670A2 (fr) * 2021-11-15 2023-05-19 The Trustees Of Princeton University Criblage de nucléases cas pour une activité nucléase modifiée
CN115927473B (zh) * 2022-07-15 2024-06-18 上海本导基因技术有限公司 一种用于单纯疱疹病毒感染性疾病的基因治疗药物
CN115458063B (zh) * 2022-09-22 2023-06-16 云舟生物科技(广州)股份有限公司 载体推荐方法、系统、计算机存储介质及电子设备
WO2024113302A1 (fr) * 2022-12-01 2024-06-06 深圳先进技术研究院 Arng ciblant des gènes essentiels du hsv, système d'édition de gène crispr/cas, système d'administration et utilisation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6103489A (en) 1997-03-21 2000-08-15 University Of Hawaii Cell-free protein synthesis system with protein translocation and processing
EP1235842A4 (fr) 1999-10-15 2003-04-23 Univ Massachusetts Genes de voies d'interference d'arn en tant qu'outils d'interference genetique ciblee
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
US8481506B2 (en) * 2006-12-05 2013-07-09 Rosetta Genomics, Ltd. Nucleic acids involved in viral infection
WO2009006618A2 (fr) * 2007-07-05 2009-01-08 University Of Kansas Protéine mutante icp0 du virus de l'herpès simplex.
US20120171191A1 (en) * 2009-05-26 2012-07-05 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
RS64622B1 (sr) * 2012-05-25 2023-10-31 Univ California Metode i sastavi za modifikaciju ciljane dnk upravljenu pomoću rnk i za modulaciju transkripcije upravljanu rnk
CN104995302B (zh) * 2013-01-16 2021-08-31 爱默蕾大学 Cas9-核酸复合物及其相关用途
JP6670743B2 (ja) * 2013-05-29 2020-03-25 セレクティスＣｅｌｌｅｃｔｉｓ Ｉｉ型ｃｒｉｓｐｒシステムにおける新規のコンパクトなｃａｓ９足場
MX2016007324A (es) * 2013-12-12 2017-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapeuticas de los sistemas y composiciones crispr-cas para actuar sobre hbv y trastornos y enfermedades virales.
RU2016136977A (ru) * 2014-02-18 2018-03-20 Дьюк Юниверсити Композиции для инактивации репликации вируса и способы их получения и применения
WO2015153789A1 (fr) * 2014-04-01 2015-10-08 Editas Medicine, Inc. Méthodes et compositions liées à crispr/cas pour le traitement du virus de l'herpès simplex type 1 (hsv -1)
WO2015153791A1 (fr) * 2014-04-01 2015-10-08 Editas Medicine, Inc. Méthodes et compositions relatives à crispr/cas pour traiter le virus de l'herpès simplex de type 2 (vhs-2)
WO2015153889A2 (fr) * 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Substances et procédés pour le traitement d'une infection virale latente
AU2016343991B2 (en) * 2015-10-30 2022-12-01 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating herpes simplex virus

Also Published As

Publication number Publication date
AU2016206692B2 (en) 2022-03-17
JP2022023099A (ja) 2022-02-07
AU2016206692A1 (en) 2017-08-10
WO2016115355A1 (fr) 2016-07-21
JP7522088B2 (ja) 2024-07-24
ZA201704840B (en) 2019-08-28
HK1249056A1 (zh) 2018-10-26
CA2973722A1 (fr) 2016-07-21
US20180000970A1 (en) 2018-01-04
MX2017009324A (es) 2017-11-16
BR112017014986A2 (pt) 2018-03-20
EP3244932A4 (fr) 2018-07-18
CN107580504A (zh) 2018-01-12
JP7305301B2 (ja) 2023-07-10
EP3244932A1 (fr) 2017-11-22
JP2018507183A (ja) 2018-03-15

Similar Documents

Publication Publication Date Title
MA41349A (fr) Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
MA49463A (fr) Vaccin contre le virus de l'herpès simplex
MA46024A (fr) Vaccin contre le virus de l'herpès simplex
MA50813A (fr) Vaccins contre le virus d'epstein-barr
MA40880A (fr) Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus
EP3426633A4 (fr) Élimination du virus de l'hépatite b par des agents antiviraux
MA45863A (fr) Agent arni contre l'infection par le virus de l'hépatite b
EP3331571A4 (fr) Compositions et procédés pour traiter des infections virales
EP3490574B8 (fr) Expression de pten-long avec des virus oncolytiques
WO2016099982A3 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
EA201790534A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
EP3577132A4 (fr) Thérapie à base de virus oncolytique
EP3525821A4 (fr) Anticorps multispécifiques ciblant le virus de l'immunodéficience humaine et leurs procédés d'utilisation
EP3309251A4 (fr) Vecteur viral de parainfluenza de type 2 humain et vaccin
IL267639A (en) Oncolytic viruses and therapeutic molecules
SG11202004725PA (en) Protein purification and virus inactivation with alkyl glycosides
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
BR112017027770A2 (pt) composições e métodos para modular infecção viral
GB201504251D0 (en) Oncolytic herpes simplex virus infected cells
EP3710018A4 (fr) Virus oncolytiques décorés par une fraction de ciblage
EP3416680A4 (fr) Compositions et méthodes d'utilisation d'inhibiteurs des stat1/3 avec un virus oncolytique de l'herpès
DK3469071T3 (da) Herpesvirus med modificeret glycoprotein D
GB201520345D0 (en) Herpes simplex viruses
EP3261654A4 (fr) Réponse d'hypersensibilité de type retardé non spécifique pour traiter une infection par le virus herpès simplex